Chronic respiratory diseases affect millions of people every day. According to the World
Health Organization estimates,~ 235 million people suffer from asthma,~ 64 million suffer …

Abstract Selective phosphodiesterase 4 (PDE4) inhibitors have been extensively studied for
the treatment of various respiratory diseases due to their broad anti-inflammatory and/or …

PDE4 inhibitors can suppress a variety of inflammatory cell functions that contribute to their
anti-inflammatory actions in respiratory diseases like chronic obstructive pulmonary disease …

Phosphodiesterase (PDE) 4 inhibitors have been in development as a novel anti-
inflammatory therapy for more than 20 years, with asthma and chronic obstructive pulmonary …

Introduction: Phosphodiesterase (PDE) inhibitors modulate lung inflammation and cause
bronchodilation by increasing intracellular cyclic adenosine 3', 5'-monophosphate in airway …

Phosphodiesterase 4 (PDE4) is a member of the PDE enzyme superfamily that inactivates
cyclic adenosine monophosphate and cyclic guanosine monophosphate, and is the main …

Asthma and chronic obstructive pulmonary disease (COPD) are common chronic respiratory
diseases. Both diseases have incompletely distinct pathophysiology, clinical manifestation …

Phosphodiesterases (PDEs) are a superfamily of enzymes that catalyze the breakdown of
cAMP and/or cyclic guanosine monophosphate (GMP) to their inactive form. PDE4 is the …

Current drug treatments for chronic obstructive pulmonary disease (COPD) focus on
managing symptoms of the disease and include short-and long-acting β2-agonists …

Selective phosphodiesterase (PDE) inhibitors are a class of nonsteroid anti-inflammatory
drugs for treating chronic inflammatory diseases. Modulation of systemic and airway …